Form 4 for VIVS VivoSim Labs, INC.
Accepted 2024-08-07 00:00:00 ET · period of report 2024-08-05 · accession 0000950170-24-092719 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-08-07 | 2024-08-07 | VIVS | Murphy Keith | EXECUTIVE COB, Dir | A - Grant | $0.00 | +19.6K | 132.6K | +17% | $0 |
| DM | 2024-08-07 | 2024-08-05 | VIVS | Murphy Keith | EXECUTIVE COB, Dir | A - Grant | $0.00 | +718.7K | 574.9K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-08-07 | A | A | 19,607 | $0.00 | 132,641 | D | — | — | (F1) The reported securities are represented by restricted stock units, which shall vest on the earlier of August 7, 2025 or the date of the annual meeting of stockholders held by the Issuer in 2025, subject to acceleration in the event of a change of control. |
| 2 | Derivative | Options (right to buy) | 2024-08-05 | A | A | 143,731 | $0.00 | 143,731 | D | $0.54 · — to 2034-08-05 | 143,731 Common Stock | (F3) The option becomes exercisable if, after the grant date, the closing sales price of the Common Stock, as reported on the Nasdaq Capital Market (based on a 90-trading day average), is at least $1.53 (subject to adjustment for stock splits), as confirmed by the Board of Directors or a committee thereof. |
| 3 | Derivative | Options (right to buy) | 2024-08-05 | A | A | 574,923 | $0.00 | 574,923 | D | $0.54 · — to 2034-08-05 | 574,923 Common Stock | (F2) The option vests in 3 equal annual installments on each of August 5, 2025, August 5, 2026 and August 5, 2027. |